A Fast and Efficient Approach to Obtaining High-Purity Glioma Stem Cell Culture

Frontiers in Genetics

Hua He²  Min Wang³  Meng-Han Zhang⁴  Wei-Hua Zhang⁴  Lu-Ying Zhu⁴  Li-Ming Yu⁴  Wei Huang⁴  Xin-Xin Han⁴  Zhengliang Gao⁵  Chunhui Cai⁵  Jie Ren⁵  Dai-Yu Hu⁵ 

[1] Department of Neurosurgery, Changzheng Hospital, Second Military Medical University, Shanghai, China;Department of Neurosurgery, Third Affiliated Hospital of Second Military Medical University, Shanghai, China;School of Medicine, Jiaxing University, Jiaxing, China;Shanghai Key Laboratory of Craniomaxillofacial Development and Diseases, Shanghai Stomatological Hospital, Fudan University, Shanghai, China;Tongji University Cancer Center, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China;

关键词: glioblastoma;    cancer stem cell;    neural stem cell;    p53;    tubulin beta 6 class V;    SRY-box containing gene 2;   

DOI  :  10.3389/fgene.2021.639858

来源: DOAJ

【 摘 要 】

Glioma is the most common and malignant primary brain tumor. Patients with malignant glioma usually have a poor prognosis due to drug resistance and disease relapse. Cancer stem cells contribute to glioma initiation, progression, resistance, and relapse. Hence, quick identification and efficient understanding of glioma stem cells (GSCs) are of profound importance for therapeutic strategies and outcomes. Ideally, therapeutic approaches will only kill cancer stem cells without harming normal neural stem cells (NSCs) that can inhibit GSCs and are often beneficial. It is key to identify the differences between cancer stem cells and normal NSCs. However, reports detailing an efficient and uniform protocol are scarce, as are comparisons between normal neural and cancer stem cells. Here, we compared different protocols and developed a fast and efficient approach to obtaining high-purity glioma stem cell by tracking observation and optimizing culture conditions. We examined the proliferative and differentiative properties confirming the identities of the GSCs with relevant markers such as Ki67, SRY-box containing gene 2, an intermediate filament protein member nestin, glial fibrillary acidic protein, and s100 calcium-binding protein (s100-beta). Finally, we identified distinct expression differences between GSCs and normal NSCs including cyclin-dependent kinase 4 and tumor protein p53. This study comprehensively describes the features of GSCs, their properties, and regulatory genes with expression differences between them and normal stem cells. Effective approaches to quickly obtaining high-quality GSCs from patients should have the potential to not only help understand the diseases and the resistances but also enable target drug screening and personalized medicine for brain tumor treatment.

【 授权许可】

Unknown